Non-invasive positive pressure ventilation (NPPV) is a well established therapy for acute respiratory failure in patients with chronic obstructive pulmonary disease, however its role in post-extubation period is uncertain. The objective of this study was to find the effect of NPPV on rate of re-intubation, intensive care unit and hospital stay, and physiological parameters in severe chronic obstructive pulmonary disease patients after planned extubation. Forty patients with severe chronic obstructive pulmonary disease were randomised immediately after planned extubation to receive NPPV (n=20) or conventional therapy (n=20). NPPV was delivered with mean levels of inspiratory positive-airway pressure of 12.10±1.37 cmH 2 O and expiratory positive-airway pressure of 6.50±1.00 cmH 2 O for a mean period of 34.75±10 hours for 7 to 11 hours/day. Patients in conventional therapy group received usual treatment. Reintubation rate among NPPV (15%) and conventional (25%) were similar (P=0.44). The duration of intensive care unit stay after extubation (2. 05±2.15 vs 1.55±0.82 days, P=0.34) and hospital stay (16.10±6.29 vs 18.25±7.91 days, P=0.34) in both groups were comparable. Given the load of chronic obstructive pulmonary disease patients and wide availability of NPPV, it is safe to recommend its use in these patients soon after extubation, although clear benefit is not documented in this study.
Chronic obstructive pulmonary disease (COPD) is currently the fourth leading cause of death worldwide, and both the worldwide prevalence and mortality associated with COPD are anticipated to increase in the coming decades 1 . Many of the patients with this disease require mechanical ventilation during exacerbation of the disease and intensive care unit (ICU) physicians face great difficulty in weaning these patients from mechanical ventilation 2, 3 . Among patients who are weaned from mechanical ventilation, reintubation may be necessary for management of respiratory failure after planned extubation in as many as 6 to 23% of patients within 48 to 72 hours [4] [5] [6] [7] . Although reintubation could indicate increased disease severity, at the same time it exposes the patient to injury to the upper airway, nosocomial pneumonia, extended hospital stay and mortality 7, 8 .
For several years the use of non-invasive positive pressure ventilation (NPPV) in patients with acute respiratory failure with COPD has been the standard of care 1 . However, its role in the weaning process is still evolving. During the weaning process NPPV may be applied in three settings: 1) in patients who developed respiratory distress/failure during postextubation period 6,9 ; 2) as an adjunct to weaning patients from mechanical ventilation by early extubation directly to NPPV 10, 11 ; or 3) as a routine application of NPPV in all or selected high risk patients who were extubated at the time they fulfilled the standard criteria 12, 13 . Hilbert and colleagues used NPPV in patients with postextubation hypercapnic respiratory insufficiency and compared the outcome with established data 14 . NPPV was offered if patients developed postextubation respiratory distress within 72 hours of planned extubation. They demonstrated a reduction in the rate of reintubation and ICU stay without any difference in mortality. Subsequently, Keenan et al in a heterogenous patient group used NPPV after postextubation distress within 48 hours of extubation 9 . The study concluded that there was no difference in the rate of re-intubation, duration of ICU or hospital stay and mortality. Nava et al showed that NPPV use was associated with a lower intubation rate and a reduction in risk of ICU mortality in patients who developed respiratory failure during the post-extubation period 12 . However, Esteban and colleagues in a randomised multicentre trial found that the use of NPPV in a heterogeneous group of patients with respiratory distress after extubation led to higher mortality in this group 6 . This study was discontinued due to adverse outcomes in the intervention group. It was thought that unfavourable outcomes in this trial were due to unduly prolonged trials with NPPV.
Ventilator dependency or weaning failure results from an imbalance between respiratory demand and respiratory muscle capacity. NPPV may not be effective in breaking this cycle of deterioration which ultimately leads to reintubation 15, 16 . Previous studies have shown that NPPV is most useful in the setting of respiratory failure secondary to COPD 17, 18 . Therefore we hypothesised that prompt use of NPPV immediately after planned extubation in hypercapnic COPD patients could reduce the reintubation rate. We also studied the effect of this treatment modality on other outcome parameters such as duration of ICU and hospital stay after extubation and improvement in physiological parameters.
MATERIAL AND METHODS
This randomised controlled clinical trial was conducted from November 2001 to December 2003 with patients in the ICU of a tertiary care hospital in India. Patients of any age and either gender with acute exacerbation of COPD with type-2 respiratory failure, who were on invasive mechanical ventilation for more than 48 hours and who had planned extubation were eligible for this study.
Patients were weaned using pressure support ventilation, synchronised intermittent mandatory ventilation or T-piece trial. Patients were extubated when they required synchronised intermittent mandatory ventilation at a rate of <6 breaths/ minute, pressure support <7 cmH 2 O or sustaining T-piece trial for a minimum of two hours. The criteria for weaning were: improvement of the cause of acute respiratory failure that led to use of ventilatory support, correction of arterial hypoxaemia (arterial partial pressure of oxygen [P a O 2 ] of greater than 60 mmHg) with fraction of inspired oxygen (FiO 2 ) of less than or equal to 0.4, and arterial partial pressure of carbon dioxide (P a CO 2 ) of less than 60 mmHg, not requiring vasoactive drugs, having an adequate level of consciousness (Glasgow coma score of 13 or more), cough reflex and not requiring sedation. Patients with cardiopulmonary instability (hypo-tension, myocardial ischaemia/infarct or arrhythmia), copious secretions, altered state of consciousness, tracheostomy, uncooperativeness and patients who had prior reintubation during the current admission were excluded from the study. This study was approved by the institutional ethics committee.
Patients were included in the study after an informed consent form was signed by the patient or a family member. At the time of extubation, patients were randomised to receive either NPPV or conventional therapy (oxygen by nasal prongs or mask) by opening a sealed envelope containing a code provided by the principal investigator. NPPV was given with well-fitting full-facemask by BiPAP ventilatory system (Nellcor Puritan Bennett, Carlsbad, CA, USA). After explaining the procedure to the patient and/or relative, a NPPV BiPAP with a preset inspiratory positive airway pressure of 8 cmH 2 O and expiratory positive airway pressure of 4 cmH 2 O was commenced. The position of the head of the bed was kept at 45°. Ventilator pressure settings were adjusted according to O 2 saturation and arterial blood gas analysis. All patients were encouraged to use the NPPV for at least seven hours a day. NPPV was interrupted for eating and drinking. Each patient was monitored closely for the initial hour. Patients' discomfort and any intolerance to the mask was noted. Clinical monitoring included heart rate, respiratory rate, blood pressure and appearance of respiratory distress such as the use of accessory muscles of respiration.
NPPV was discontinued in case of inability to tolerate the mask because of discomfort, deterioration in ventilatory parameters (rise in PCO 2 , fall in pH or P a O 2 ), deteriorating state of consciousness or haemodynamic instability. Patients assigned to the conventional group received oxygen by means of nasal prongs or oronasal mask. The oxygen flow was adjusted to keep an oxygen saturation of at least 88%. Both groups received bronchodilator, antibiotics and corticosteroids as decided by the ICU physician. The decision to reintubate was taken by the treating physician in the ICU and the investigating team was not involved.
RESULTS
Forty patients with COPD who underwent planned extubation after at least 48 hours of mechanical ventilation underwent random allocation to NPPV or conventional therapy. The weaning from mechanical ventilation was done by pressure support ventilation (13 vs 12), T-piece trial (four each) or synchronised intermittent mandatory ventilation (three and four) in the NPPV and conventional treatment group respectively. General clinical characteristics and physiological variables of patients at entry into the study were comparable and are shown in Table 1 All patients were treated with inhaled bronchodilators (beta-2 agonists and anticholinergics), inhaled corticosteroids and antibiotics. Intravenous corticosteroids were given to 23 patients (10 and 13 in the NPPV and conventional therapy groups, respectively) with dose ranging from 300 to 600 mg of hydrocortisone per day.
Non-invasive positive pressure ventilation was delivered for a mean period of 34.75±10 hours in patients assigned to this group. The duration of NPPV varied from 7 to 11 hours/day with a mean duration of 7.96±2.10 hours/day. Mean levels of inspiratory and expiratory positive-airway pressure in these patients were 12.10±1.37 cm of H 2 O and 6.50±1.00 cm of H 2 O, respectively. Five patients tolerated NPPV for six hours or less.
Effect of NPPV on various outcome parameters
In the NPPV group, three (15%) patients required reintubation, one each due to claustrophobia (nontolerance), persistent hypoxaemia and rising P a CO 2 with hypoxaemia. Among these patients, one patient required tracheostomy and was later discharged on home oxygen therapy, while the other two patients were successfully weaned. In the conventional therapy group, five (25%) patients required reintubation, two due to rising P a CO 2 and falling P a O 2 , two due to deterioration in level of consciousness and one due to copious secretions. Among these five patients, four patients were successfully weaned and discharged (one required tracheostomy) and one patient had a cardiac arrest and died.
We observed that duration of ICU and hospital stay after extubation, and total duration of hospital stay were similar in the two groups ( Table 2) . Although the total duration of hospital stay was less (approximately two days) among the patients who received NPPV as compared to conventional therapy, this was not statistically significant. 
Effect of NPPV on physiological and arterial blood gas parameters
The trends and comparisons of various physiological variables, blood gas parameters, heart rate and respiratory rate of both groups are shown in Figures  2 to 7 . We observed that all blood gas parameters, i.e. pH, P a CO 2 , P a O 2 , and oxygen saturation in both groups were comparable through-out the postextubation period. Similarly, respiratory rate and heart rate during the post extubation period were also comparable between two groups (Figures 6 and 7) .
DISCUSSION
We used NPPV in patients with COPD with acute respiratory failure on mechanical ventilation after planned extubation in order to demonstrate the benefits in rate of reintubation, ICU and hospital stay and blood gas parameters. NPPV was used immediately after planned extubation. This was a prospective randomised controlled trial where the investigating team was not involved in the decision to extubate patients. It was observed that more patients (25%) managed with conventional treatment required reintubation compared with those treated with NPPV (15%). Although this was not statistically significant, the study was not powered to determine such a difference. Hospital stay was reduced by two days, but this was not statistically significant. In hospitals such as ours there is always shortage of beds, so any reduction in duration of stay in hospital or ICU is important. There were no significant complications related to use of NPPV.
Hypercapnia is a very useful indicator in patients with COPD. Pre-intubation in patients with high P a CO 2 levels reflects advanced disease with severe impairment of pulmonary function 1 . During the period of recovery, hypercapnia can be a good indicator of risk of clinical deterioration 19, 20 . Our patients had advanced COPD as indicated by severe pre-intubation hypercapnia (mean P a CO 2 >80 mmHg) and were at high risk of respiratory failure as indicated by persistent hypercapnia at the time of extubation (mean P a CO 2 >50 mmHg). NPPV use in this high risk group was associated with a significant fall in P a CO 2 from 50.61±4.36 mmHg at the time of extubation to 41.97±6.13 mmHg (P=0.003) at discharge. These results are similar to other studies which demonstrate the positive impact of NPPV on blood gas parameters 21, 22 . However, in our study, improvement in blood gases by NPPV use did not prove superior to standard therapy in averting reintubation, or reducing ICU and hospital stay.
Prior studies have not focussed exclusively on COPD patients and hence shown variable results. These studies have included heterogenous groups of patients with respiratory failure and have also used NPPV in different settings 6, 9, [11] [12] [13] [14] 20, 23 . The studies where NPPV was used immediately after extubation showed positive results 10, 13 . Girault et al demonstrated that NPPV may be used for early removal of the endotracheal tube without increasing the rate of weaning failure 10 . Similarly, Ferrer et al showed that early NPPV use reduced the risk of respiratory failure and 90-day mortality in patients with hypercapnia during spontaneous breathing trial 13 . Both these studies bear resemblance to our study with regard to timing of NPPV application, in that in both studies it was used immediately after extubation. However, there are also significant differences. For example, in the first trial investigators used NPPV in patients who failed spontaneous breathing trials as assessed by clinical and blood gas parameters 10 , replacing invasive mechanical ventilation with NPPV in patients who were by conventional assessment unfit for extubation. The second trial more closely resembles ours, where NPPV was used in patients who were showing hypercapnia during spontaneous breathing trials, but otherwise fit for extubation 13 . However, this study also included patients with respiratory failure of multiple aetiologies such as COPD, bronchiectasis, congestive cardiac failure and cancer, unlike ours which had only COPD patients. These differences might be responsible for the difference in final outcome. This is the first randomised controlled trial which was conducted exclusively on COPD patients where NPPV was used immediately after planned extubation. The success of NPPV may be influenced by many factors such as the type of mask used, mode of ventilation and compliance to the treatment, as well as severity of the disease 15, 16 . Another important factor which can influence the success of NPPV is the ventilator design 13, 20, 24 . NPPV which has control of FiO 2 , effective leak compensation, realtime assessment of mask pressure and a sensitive and rapid flow-by trigger are important characteristics 13, 20 . The NPPV used in our study did not have real-time assessment of mask pressure and effective leak compensation. Initial ventilator setting may be an important determinant of compliance and success of NPPV. In our study the initial inspiratory positiveairway pressure and expiratory positive-airway pressure were 8 and 4 cmH 2 O, respectively. This has been a routine practice in our ICU. We have found this strategy quite useful with good compliance (as in the present study). The aetiology of the respiratory failure may be an important factor in determining the final outcome in patients who are admitted to ICU. In this cohort, the severity of COPD was high, as indicated by the high mean P a CO 2 (>80 mmHg) at the time of endotracheal intubation. This can be another factor along with the small sample size which might have contributed to differences in outcome compared to other studies.
CONCLUSION
Although there is no statistically significant difference in rate of reintubation, NPPV use was found to be safe and reduced hospital stay by approximately two days. There was a non-significant decrease in the need for reintubation (15% vs 25%) but the study was not powered to detect such a difference. However, given the known complications of reintubation, this observation has sufficient importance to suggest a need for further, larger studies. Given the load of COPD patients and wide availability of NPPV in all the settings, it is safe to recommend its use in these patients soon after extubation, although clear benefit is not documented in this study.
